blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3046917

EP3046917 - QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.09.2018
Database last updated on 14.09.2024
FormerThe patent has been granted
Status updated on  06.10.2017
FormerGrant of patent is intended
Status updated on  23.05.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Pierre Fabre Médicament
45, Place Abel Gance
92100 Boulogne-Billancourt / FR
For all designated states
Centre National de la Recherche Scientifique (C.N.R.S.)
3, rue Michel-Ange
75016 Paris / FR
[2017/45]
Former [2016/30]For all designated states
Pierre Fabre Médicament
45, Place Abel Gance
92100 Boulogne-Billancourt / FR
For all designated states
Centre National de la Recherche Scientifique (CNRS)
3 rue Michel-Ange
75016 Paris / FR
Inventor(s)01 / HALBY, Ludovic
6 Rue des Menuisiers
F-31400 Toulouse / FR
02 / ARIMONDO, Paola Barbara
7 Rue Temponières
F-31000 Toulouse / FR
 [2016/30]
Representative(s)Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
[N/P]
Former [2016/30]Regimbeau
20, rue de Chazelles
75847 Paris Cedex 17 / FR
Application number, filing date14771312.719.09.2014
[2016/30]
WO2014EP70011
Priority number, dateEP2013030628119.09.2013         Original published format: EP 13306281
[2016/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015040169
Date:26.03.2015
Language:EN
[2015/12]
Type: A1 Application with search report 
No.:EP3046917
Date:27.07.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 26.03.2015 takes the place of the publication of the European patent application.
[2016/30]
Type: B1 Patent specification 
No.:EP3046917
Date:08.11.2017
Language:EN
[2017/45]
Search report(s)International search report - published on:EP26.03.2015
ClassificationIPC:C07D401/14, C07D401/12, A61K31/517, A61P35/00
[2016/30]
CPC:
C07D401/12 (EP,US); A61K31/517 (EP,US); A61P35/00 (EP);
C07D401/14 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/30]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:CHINAZOLINDERIVATE UND IHRE VERWENDUNG ALS DNA METHYLTRANSFERASE INHIBITOREN[2017/23]
English:QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS[2016/30]
French:DÉRIVÉS DE QUINAZOLINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS D'ADN MÉTHYLTRANSFÉRASE[2017/23]
Former [2016/30]CHINAZOLINDERIVATE UND DEREN VERWENDUNG ALS DNA-METHYLTRANSFERASEINHIBITOREN
Former [2016/30]DÉRIVÉS DE QUINAZOLINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE L'ADN MÉTHYLTRANSFÉRASE
Entry into regional phase31.03.2016National basic fee paid 
31.03.2016Designation fee(s) paid 
31.03.2016Examination fee paid 
Examination procedure31.03.2016Examination requested  [2016/30]
02.08.2016Amendment by applicant (claims and/or description)
24.05.2017Communication of intention to grant the patent
21.09.2017Fee for grant paid
21.09.2017Fee for publishing/printing paid
21.09.2017Receipt of the translation of the claim(s)
Opposition(s)09.08.2018No opposition filed within time limit [2018/42]
Fees paidRenewal fee
25.08.2016Renewal fee patent year 03
28.09.2017Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.09.2014
AL08.11.2017
AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
MK08.11.2017
PL08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
[2020/34]
Former [2020/31]HU19.09.2014
AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
MK08.11.2017
PL08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2020/30]HU19.09.2014
AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PL08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2020/28]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PL08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2020/16]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2019/24]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/52]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/40]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/37]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
PL08.11.2017
RS08.11.2017
SE08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/35]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
RS08.11.2017
SE08.11.2017
SK08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/24]AT08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
RS08.11.2017
SE08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/22]FI08.11.2017
LT08.11.2017
NO08.02.2018
Cited inInternational search[A]WO2006078752  (METHYLGENE INC [CA], et al) [A] 1-18 * the whole document *;
 [A]WO2009049132  (SUPERGEN INC [US], et al) [A] 1-18 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.